Functional daytime incontinence: pharmacological treatment

Scand J Urol Nephrol Suppl. 1992:141:108-14; discussion 115-6.

Abstract

The basis for the treatment of functional daytime incontinence in children is the bladder regimen, i.e. to teach the children to void regularly by the clock. Drug treatment may be needed as an adjunct to the regimen in children with gross detrusor instability. There is no evidence from properly controlled studies that tricyclic antidepressants or anticholinergic drugs are of value for the child with daytime wetting. Terodiline is a new drug combining anticholinergic and calcium-blocking effects. In two randomized, double-blind studies of terodiline compared with placebo in children with urge incontinence (i.e. functional day wetting), continence improved significantly over placebo in the terodiline group. Only a few mild adverse reactions were noted. Children with symptomatic urinary tract infection and day wetting should receive chemotherapy, but covert bacteriuria should best be left untreated. There is no evidence that eradication of the bacteriuria improves continence. Instead, there is a great risk of symptomatic recurrence of the urinary tract infection after antibacterial treatment.

Publication types

  • Review

MeSH terms

  • Butylamines / therapeutic use*
  • Calcium Channel Blockers / therapeutic use*
  • Child
  • Humans
  • Mandelic Acids / therapeutic use*
  • Parasympatholytics / therapeutic use*
  • Urinary Incontinence / drug therapy*
  • Urinary Incontinence / etiology
  • Urinary Tract Infections / complications

Substances

  • Butylamines
  • Calcium Channel Blockers
  • Mandelic Acids
  • Parasympatholytics
  • terodiline
  • oxybutynin